Developer of gene therapies for the treatment of multiple disease conditions. The company is focusing on gene therapy drugs such as gene replacement and gene editing for rare single-gene genetic diseases. The company's pipeline includes HG-001, HG-202, HG-004, HG-203 for neurodegenerative diseases, visual impairment, and hearing impairment. Founded in 2018, headquartered in Pudong, China. The company has raised $18.5M in funding at the series c stage. The company operates in the Genomics sector with additional focus on Neurology. Its business model centers on Diversified. Founded in 2018, headquartered in Pudong, China. The company has raised $18.5M at the Series C stage. Backed by investors including Kunlun Capital, CD Capital, Sherpa Venture Capital, WuXi AppTec, HM Venture Partners and others.
← All startups
Huida
Series CDeveloper of gene therapies for the treatment of multiple disease conditions. The company is focusing on gene therapy drugs such as gene replacement and gene editing for rare single-gene genetic diseases. The company's pipeline includes HG-001, HG-202, HG-004, HG-203 for neurodegenerative diseases, visual impairment, and hearing impairment. Founded in 2018, headquartered in Pudong, China. The company has raised…
About
Business model
Neurology > Drugs > Neurodegenerative > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Kunlun CapitalCD CapitalSherpa Venture CapitalWuXi AppTecHM Venture PartnersYahui CapitalAlwin Capital
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.